Angelos M Stergiou

US Patent:

20090297623, Dec 3, 2009

Filed:

Aug 3, 2009

Appl. No.:

12/534575

Inventors:

ANGELOS M. STERGIOU - New York NY, US

Assignee:

ACCENTIA BIOPHARMACEUTICALS, INC - Tampa FL

International Classification:

A61K 33/42

US Classification:

424606

Abstract:

The present invention is directed to compositions, devices, and methods for non-irritatively treating and preventing mucositis, such as chronic rhinosinusitis (CRS). Some aspects of the invention concern compositions comprising or consisting essentially of sodium phosphate buffer (e.g., sodium phosphate dibasic and sodium phosphate monobasic) and calcium carbonate; mucoadministration devices and kits containing such compositions; and methods for treating or preventing mucositis conditions such as CRS, comprising mucoadministering a composition of the invention to a subject in need thereof.

US Patent:

20200121789, Apr 23, 2020

Filed:

Oct 19, 2019

Appl. No.:

16/658047

Inventors:

- Dover DE, US
ANGELOS M. STERGIOU - NEW YORK NY, US
NICHOLAS J. SARLIS - NEW YORK NY, US

International Classification:

A61K 39/395
A61K 39/00
A61P 35/00
A61K 9/00
A61K 39/39

Abstract:

The present invention concerns a method for treating triple-negative breast cancer (TNBC) in an individual, and/or for inducing an immune response to HER2/neu in an individual with a triple-negative breast cancer expressing low levels of HER2/neu, the method comprising administering to the individual: (a) an effective amount of trastuzumab, or derivative thereof; and (b) an effective amount of nelipepimut-S, or variant thereof, optionally with an immunological adjuvant. Preferably, the method includes a preparatory or priming phase comprising a frequency and duration of trastuzumab or trastuzumab derivative administration sufficient to substantially increase the major histocompatibility complex (MHC)-mediated presentation of HER2 peptide fragments to the patient immune system. The invention also includes medicaments and kits for treating TNBC in an individual, and/or for inducing an immune response to HER2/neu in an individual with a TNBC expressing HER2/neu.